Literature DB >> 2230898

Drug-induced DNA damage and tumor chemosensitivity.

R J Epstein1.   

Abstract

Cytotoxic drugs act principally by damaging tumor-cell DNA. Quantitative analysis of this interaction provides a basis for understanding the biology of therapeutic cell kill as well as a rational strategy for optimizing and predicting tumor response. Recent advances have made it possible to correlate assayed DNA lesions with cytotoxicity in tumor cell lines, in animal models, and in patients with malignant disease. In addition, many of the complex interrelationships between DNA damage, DNA repair, and alterations of gene expression in response to DNA damage have been defined. Techniques for modulating DNA damage and cytotoxicity using schedule-specific cytotoxic combinations, DNA repair inhibitors, cell-cycle manipulations, and adjunctive noncytotoxic drug therapy are being developed, and critical therapeutic targets have been identified within tumor-cell subpopulations and genomic DNA alike. Most importantly, methods for predicting clinical response to cytotoxic therapy using both in vitro markers of tumor-cell sensitivity and in vivo measurements of drug-induced DNA damage are now becoming a reality. These advances can be expected to provide a strong foundation for the development of innovative cytotoxic drug strategies over the next decade.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230898     DOI: 10.1200/JCO.1990.8.12.2062

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  15 in total

Review 1.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy.

Authors:  Angelo Guainazzi; Orlando D Schärer
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

3.  Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.

Authors:  K Ye; Y Ke; N Keshava; J Shanks; J A Kapp; R R Tekmal; J Petros; H C Joshi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Effects of VEGF + Mesenchymal Stem Cells and Platelet-Rich Plasma on Inbred Rat Ovarian Functions in Cyclophosphamide-Induced Premature Ovarian Insufficiency Model.

Authors:  Birol Vural; Gokhan Duruksu; Fisun Vural; Merve Gorguc; Erdal Karaoz
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

Review 5.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

6.  Genetic disease in offspring of long-term survivors of childhood and adolescent cancer.

Authors:  J Byrne; S A Rasmussen; S C Steinhorn; R R Connelly; M H Myers; C F Lynch; J Flannery; D F Austin; F F Holmes; G E Holmes; L C Strong; J J Mulvihill
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

Review 7.  Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management.

Authors:  Dana Shanis; Melissa Merideth; Tajana Klepac Pulanic; Bipin N Savani; Minoo Battiwalla; Pamela Stratton
Journal:  Semin Hematol       Date:  2012-01       Impact factor: 3.851

Review 8.  HtrA serine proteases as potential therapeutic targets in cancer.

Authors:  Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

Review 9.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

Review 10.  Ovarian and Uterine Functions in Female Survivors of Childhood Cancers.

Authors:  Ozgur Oktem; Samuel S Kim; Ugur Selek; Glenn Schatmann; Bulent Urman
Journal:  Oncologist       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.